Table 3.
Authors (year) | Pts (n) | Non-GTR (%) | Residual tumor volume* (cm3) | FN grade 1 and 2 (%) | Observation (%) | Regrowths among observation (%) | Surgery to regrowth time* (mos) | FU time* (mos) |
---|---|---|---|---|---|---|---|---|
Haque et al. (2011) | 151 | 96/151 (64) | NA | 97 | 96/96 (100) | 20/96 (21) | 47 | 72 |
Martin et al. (2012) | 212 | 65/212 (31) | NA | 55 | 65/65 (100) | 5/65 (8) | NA | 66 |
Carlson et al. (2012) | 203 | 59/203 (29) | NA | NA | 59/59 (100) | 7/59 (12) | NA | 42 |
Chen et al. (2014) | 111 | 111/111 (100) | NA | 49 | 111/111(100) | 7/111 (6) | 41 | 45 |
Monfared et al. (2016) | 73 | 61/73 (84) | 1.1 | 81 | 61/61 (100) | 13/61 (21) | 35 | 38 |
Syed et al. (2016) | 450 | 42/450 (9) | NA | 59 | 42/42 (100) | 3/42 (7) | NA | 73 |
Troude et al. (2018) | 159 | 143/159 (90) | 0.56 | 84 | 66/143 (46) | 12/66 (18) | 37 | 59 |
Present study | 111 | 60/111 (54) | 0.36 | 77 | 53/60 (88) | 9/53 (17) | 33 | 69 |
FN facial nerve, FU follow-up, GTR gross-total resection, NA not applicable/available.
*Values shown are mean and the percentages have been rounded up.